[go: up one dir, main page]

AR026507A1 - Una formulacion de solucion acuosa de interferon alfa - Google Patents

Una formulacion de solucion acuosa de interferon alfa

Info

Publication number
AR026507A1
AR026507A1 ARP000106058A ARP000106058A AR026507A1 AR 026507 A1 AR026507 A1 AR 026507A1 AR P000106058 A ARP000106058 A AR P000106058A AR P000106058 A ARP000106058 A AR P000106058A AR 026507 A1 AR026507 A1 AR 026507A1
Authority
AR
Argentina
Prior art keywords
interferon alfa
formulation
alfa
aqueous solution
time
Prior art date
Application number
ARP000106058A
Other languages
English (en)
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR026507A1 publication Critical patent/AR026507A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Una formulacion acuosa que puede retener la actividad biologica y las porpiedades físico-químicas de interferon alfa durante un período prolongado detiempo. Más particularmente, la presente invencion se refiere a una formulacion de solucion acuosa de interderon alfa que comprende interferon alfa, unestabilizador, un agente regulador de presion osmotica, conservantes antimicrobiales elegidos del grup que comprende fenol, m-cresol y una mezcla de ellos, yun sistema amortiguador. La formulacion de solucion acuosa presenta muchas ventajas debido a que retiene la actividad de interferon alfa por un largo períodode tiempo, elimina el dano potencial al cuerpo humano al minimizar la cantidad de conservantes y es muy estable.
ARP000106058A 1999-11-19 2000-11-16 Una formulacion de solucion acuosa de interferon alfa AR026507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-1999-0051481A KR100399156B1 (ko) 1999-11-19 1999-11-19 α-인터페론의 용액제형

Publications (1)

Publication Number Publication Date
AR026507A1 true AR026507A1 (es) 2003-02-12

Family

ID=36782398

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106058A AR026507A1 (es) 1999-11-19 2000-11-16 Una formulacion de solucion acuosa de interferon alfa

Country Status (23)

Country Link
EP (1) EP1231933B1 (es)
JP (1) JP3893286B2 (es)
KR (1) KR100399156B1 (es)
CN (1) CN1203892C (es)
AR (1) AR026507A1 (es)
AT (1) ATE333891T1 (es)
AU (1) AU777994B2 (es)
BR (1) BR0015699A (es)
CA (1) CA2391889A1 (es)
CY (1) CY1105449T1 (es)
DE (1) DE60029614T2 (es)
DK (1) DK1231933T3 (es)
ES (1) ES2267584T3 (es)
HU (1) HUP0203706A3 (es)
MX (1) MXPA02005105A (es)
PE (1) PE20010903A1 (es)
PL (1) PL356406A1 (es)
PT (1) PT1231933E (es)
RU (1) RU2232595C2 (es)
TR (1) TR200201310T2 (es)
TW (1) TWI223596B (es)
WO (1) WO2001035987A1 (es)
ZA (1) ZA200204096B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
RU2270692C1 (ru) * 2004-11-04 2006-02-27 Валентина Васильевна Малиновская Пролонгированный раствор интерферона
RU2447897C2 (ru) * 2009-03-26 2012-04-20 Сергей Юрьевич Родионов Цитокинсодержащая композиция для лечения вирусных заболеваний
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
EP2575761B1 (en) * 2010-05-28 2024-08-14 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
EP2911685A2 (en) 2012-10-26 2015-09-02 Lupin Limited Stable pharmaceutical composition of peginterferon alpha-2b
CN104888196B (zh) * 2015-06-25 2018-07-06 北京三元基因药业股份有限公司 一种稳定的干扰素α多剂量笔注射液
CN105456186A (zh) * 2015-12-24 2016-04-06 杭州嘉伟生物制品有限公司 一种生理平衡液的制备方法
CN114259556B (zh) * 2021-12-24 2024-05-31 科兴生物制药股份有限公司 人干扰素α2b喷雾剂及其制备方法
CN114053397B (zh) * 2022-01-17 2022-12-20 北京三元基因药业股份有限公司 一种稳定的干扰素多剂量注射液及其制备方法
CN115068592A (zh) * 2022-06-27 2022-09-20 长春生物制品研究所有限责任公司 开封后常温稳定的重组人干扰素α1b滴眼液及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution

Also Published As

Publication number Publication date
ATE333891T1 (de) 2006-08-15
AU1421601A (en) 2001-05-30
PT1231933E (pt) 2006-10-31
HUP0203706A2 (hu) 2003-03-28
TWI223596B (en) 2004-11-11
DE60029614D1 (de) 2006-09-07
HUP0203706A3 (en) 2004-12-28
AU777994B2 (en) 2004-11-11
KR100399156B1 (ko) 2003-09-26
PE20010903A1 (es) 2001-08-31
ZA200204096B (en) 2003-02-26
JP2003514027A (ja) 2003-04-15
DE60029614T2 (de) 2007-07-12
DK1231933T3 (da) 2006-10-30
EP1231933B1 (en) 2006-07-26
ES2267584T3 (es) 2007-03-16
JP3893286B2 (ja) 2007-03-14
EP1231933A1 (en) 2002-08-21
CN1391478A (zh) 2003-01-15
BR0015699A (pt) 2002-07-23
MXPA02005105A (es) 2002-11-07
KR20010047312A (ko) 2001-06-15
RU2232595C2 (ru) 2004-07-20
CN1203892C (zh) 2005-06-01
PL356406A1 (en) 2004-06-28
TR200201310T2 (tr) 2002-09-23
CA2391889A1 (en) 2001-05-25
CY1105449T1 (el) 2010-04-28
RU2002116364A (ru) 2004-01-20
WO2001035987A1 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
AR026507A1 (es) Una formulacion de solucion acuosa de interferon alfa
GT199800142A (es) Pirimidin-4-ona y pirimidin-4-tiona novedosas como fungicida.
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
BR0209057A (pt) Composições herbicidas contendo benzoilciclohexanodionas e protetores
AR012241A1 (es) Composicion de depuracion antimicrobiana mantenible y metodos para proporcionar efectividad residual y para tratar acne.
ES2193135T3 (es) Proteinas biocidas.
WO2002085428A3 (en) Implantable osmotic pump
KR930001914A (ko) 안정화된 pvp-i 용액
ES2156155T3 (es) Derivado de pirazol.
HN2000000115A (es) Formulacion de sal comun y moxifloxacina
TW200503773A (en) Composition for external use
CO5180582A1 (es) Soluciones farmaceuticas de levosimendan
BR9807646A (pt) Composição concentrada desinfetante lìquida aquosa, e, composição desinfetante.
PE28397A1 (es) Soluciones salinas no inorganicas para administracion endonasal
EP1852114A4 (en) COMPOSITION WITH DIHOMO (GAMMA) LINE ACIDIC ACID (DGLA) AS AN ACTIVE INGREDIENTS
ES2118317T3 (es) Agente de lavado para la desinfeccion y descontaminacion de las manos a base de alcoholes aromaticos naturales.
AR032844A1 (es) Composicion herbicida
ES2169223T3 (es) Substancia anticancerosa que inhibe la metastasis cancerosa.
GT200200015A (es) Formulacion agroquimica
AR052855A1 (es) Composiciones para el cuidado bucal que contienen un extrato de eucalyptus
ES2177849T3 (es) Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer.
ECSP045123A (es) Composición para catéteres y sus usos
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
EP2062872A3 (en) Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
AR027761A1 (es) Un derivado del acido quinolonacarboxilico, las composiciones antibacterianas que lo contienen y el uso de dicho derivado para la elaboracion de drogaspara el tratamiento de enfermedades infecciosas

Legal Events

Date Code Title Description
FB Suspension of granting procedure